Several factors are favorable for an ideal therapeutic, CTL-eliciting tumor vaccine: (i) cytosolic antigen delivery, which favors the processing and cross-presentation of exogenous antigens in MHC-I pathway; (ii) synchronously adequate DC activation for antigen presentation and co-stimulation of CD8+ T cells; (iii) quantitatively sufficient number of DCs are used; and (iv) spatially are these DCs in LNs. Here, CD8A is linked to neoplasm.